Miravalles Gold Corp Com

PHOENIX, AZ / ACCESSWIRE / August 9, 2023 / The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA) ("the Company"), a pre-clinical-stage pharmaceutical development company developing a Novel synthetic THC analog. CEO of the Company, Erez Aminov, joined Stock Day host Kevin Davis following the company's NASDAQ IPO.The company's lead drug candidate, MIRA1a, is being developed to treat anxiety and cognitive decline in the elderly and chronic pain without impurities and the negative side effects associated with cannabis plant extracts, Aminov said. "MIRA1a is...

(NewsDirect) MIRA Pharmaceuticals CEO Erez Aminov, CEO joined Proactive's Stephen Gunnion as the company started trading on the Nasdaq under the ticker symbol 'MIRA'. Aminov said MIRA is making groundbreaking advancements in the cannabis industry with the development of a synthetic marijuana analog that aims to revolutionize medicinal cannabis usage. This new molecular entity, created using patented technology, offers the benefits of THC and CBD without their typical side effects, such as paranoia, anxiety, and impaired cognition. Clinical studies at John Hopkins Medical School...

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Miravalles Gold Corp. (CSE: MIRA) (OTC Pink: SSRSF) (the "Company" or "Miravalles") announces the filing of an independent technical report for its Fairfield Gold Project (the "Project") in Nayarit, Mexico.The report, titled Technical Report on the Fairfield Gold Project, has an effective date of July 31, 2026, and was prepared by Warren Robb, P.Geo., an independent Qualified Person as defined by NI 43-101. It is available under the Company's issuer profile on SEDAR+ at www.sedarplus.ca.The Fairfield Gold Project comprises fiv...